LU92992I2 - Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables - Google Patents

Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables Download PDF

Info

Publication number
LU92992I2
LU92992I2 LU92992C LU92992C LU92992I2 LU 92992 I2 LU92992 I2 LU 92992I2 LU 92992 C LU92992 C LU 92992C LU 92992 C LU92992 C LU 92992C LU 92992 I2 LU92992 I2 LU 92992I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
hypertension
diabetic
renal
primary
Prior art date
Application number
LU92992C
Other languages
English (en)
French (fr)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22352165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92992(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU92992I2 publication Critical patent/LU92992I2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Hydrogenated Pyridines (AREA)
LU92992C 1998-07-10 2016-03-07 Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables LU92992I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11389398A 1998-07-10 1998-07-10
EP99934647A EP1096932B1 (en) 1998-07-10 1999-07-09 Antihypertensive combination of valsartan and calcium channel blocker
EP07105179A EP1870098A3 (en) 1998-07-10 1999-07-09 Combined use of valsartan and calcium channel blockers for therapeutic purposes

Publications (1)

Publication Number Publication Date
LU92992I2 true LU92992I2 (fr) 2016-05-09

Family

ID=22352165

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91358C LU91358I2 (fr) 1998-07-10 2007-09-06 Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium
LU92992C LU92992I2 (fr) 1998-07-10 2016-03-07 Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91358C LU91358I2 (fr) 1998-07-10 2007-09-06 Combinaison antihypertensive a base de valsartan et d'un bloquant du canal de calcium

Country Status (32)

Country Link
EP (3) EP1870098A3 (xx)
JP (1) JP2002520274A (xx)
KR (2) KR100550167B1 (xx)
CN (2) CN1234357C (xx)
AT (1) ATE371448T1 (xx)
AU (1) AU753486B2 (xx)
BE (1) BE2016C011I2 (xx)
BR (1) BR9912021A (xx)
CA (2) CA2336822C (xx)
CY (4) CY1107779T1 (xx)
CZ (2) CZ304359B6 (xx)
DE (2) DE122007000055I1 (xx)
DK (2) DK2322174T3 (xx)
ES (2) ES2552639T3 (xx)
FR (1) FR16C0008I2 (xx)
HK (2) HK1036758A1 (xx)
HU (1) HU229383B1 (xx)
ID (1) ID27664A (xx)
IL (3) IL140665A0 (xx)
LU (2) LU91358I2 (xx)
NL (2) NL300290I2 (xx)
NO (2) NO331802B1 (xx)
NZ (2) NZ527598A (xx)
PL (1) PL194604B1 (xx)
PT (2) PT2322174E (xx)
RU (3) RU2243768C2 (xx)
SG (1) SG142116A1 (xx)
SI (2) SI1096932T1 (xx)
SK (1) SK285863B6 (xx)
TR (1) TR200100062T2 (xx)
WO (1) WO2000002543A2 (xx)
ZA (1) ZA200100232B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
CZ293257B6 (cs) * 1998-12-23 2004-03-17 Novartis Ag Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
WO2000066161A1 (fr) 1999-04-28 2000-11-09 Takeda Chemical Industries, Ltd. Preventifs / remedes / inhibiteurs de progression pour retinopathie simplex ou retinopathie preproliferante
DE60037192T2 (de) * 1999-07-21 2008-05-15 Takeda Pharmaceutical Co. Ltd. Mittel zur verbesserung der erkrankungen nach zerebralen durchblutungsstörungen sowie zur verhinderung deren fortschreitens
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001062741A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Tetrahydronaphtalene derivatives and their use
WO2001062740A1 (en) * 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
WO2001076574A2 (en) * 2000-04-12 2001-10-18 Novartis Ag Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
BR0108823A (pt) * 2000-12-29 2002-12-10 Osmotica Corp Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
CA2463758A1 (en) * 2001-10-18 2003-05-01 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20030180712A1 (en) * 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
US20040138306A1 (en) 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
CN100444840C (zh) 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
BRPI0410374A (pt) * 2003-05-16 2006-06-13 Novartis Ag composição farmacêutica que compreende valsartano
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
US20050209288A1 (en) * 2004-01-12 2005-09-22 Grogan Donna R Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use
CN100364532C (zh) * 2004-09-30 2008-01-30 江苏恒瑞医药股份有限公司 包含氨氯地平和血管紧张素ⅱ受体抑制剂的组合物
PT1874311E (pt) 2005-04-15 2011-11-25 Res & Innovation S P A Método para prevenir, retardar ou reverter a deposição anómala de amilóide
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
GB0520405D0 (en) * 2005-10-07 2005-11-16 Imp College Innovations Ltd Biological agents and method
CN101300030A (zh) * 2005-11-08 2008-11-05 诺瓦提斯公司 血管紧张素ⅱ受体阻滞剂、钙通道阻滞剂和另一活性物质的组合产品
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
EP2214666B1 (en) 2007-10-05 2013-12-11 Alzheimer's Institute of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
CN101433536A (zh) * 2007-11-12 2009-05-20 北京瑞康医药技术有限公司 含有烟酸氨氯地平和沙坦类药物的治疗组合物
AU2008344891A1 (en) * 2007-12-31 2009-07-09 Lupin Limited Pharmaceutical compositions of amlodipine and valsartan
WO2010006103A1 (en) * 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
IT1400309B1 (it) 2010-05-10 2013-05-24 Menarini Int Operations Lu Sa Associazione di inibitori della xantina ossidasi e calcio antagonisti e loro uso.
PE20141049A1 (es) * 2011-04-12 2014-09-05 Boryung Pharm Composicion farmaceutica antihipertensiva
BR112014003117A2 (pt) 2011-08-12 2017-06-13 Boehringer Ingelheim Vetmedica Gmbh inibidores da corrente funny (if) para uso em um método de tratamento e prevenção de insuficiência cardíaca em felino
WO2013147137A1 (ja) * 2012-03-30 2013-10-03 味の素株式会社 心不全の治療剤
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
WO2016073179A2 (en) * 2014-10-23 2016-05-12 The Trustees Of The University Of Pennsylvania Novel chronotherapy based on circadian rhythms
RU2616213C2 (ru) * 2015-07-10 2017-04-13 Государственное бюджетное образовательное учреждение высшего профессионального образования "Южно-Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ЮУГМУ Минздрава России) Способ коррекции дисфункции факторов врожденного и адаптивного иммунитета при хронической почечной недостаточности в эксперименте
AU2016344018B2 (en) * 2015-10-31 2019-02-28 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
CN105287550A (zh) * 2015-11-19 2016-02-03 哈尔滨圣吉药业股份有限公司 一种缬沙坦/非洛地平复方制剂及其制备方法
US20230218583A1 (en) * 2020-04-17 2023-07-13 Honeybrains, Llc Compositions and methods for treating neuropsychiatric disorders
US20240299405A1 (en) * 2020-05-28 2024-09-12 Hangzhou Qian Biotechnology Ltd Application of atp potassium channel modifier in preparation of anti-diabetic nephropathy drug

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654372A (en) * 1986-01-10 1987-03-31 Warner-Lambert Company Method for using verapamil for treating stroke
GB8608335D0 (en) 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
DE122007000050I1 (de) * 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
NZ242724A (en) 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
WO1993017682A1 (en) * 1992-03-04 1993-09-16 Abbott Laboratories Angiotensin ii receptor antagonists
PL307258A1 (en) * 1992-07-27 1995-05-15 Pfizer Peptides capable to block calcium canals with agelenopsis aperta
US5264447A (en) * 1992-09-01 1993-11-23 Merck & Co., Inc. Angiotensin II antagonist
US5721263A (en) * 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
AU1423795A (en) * 1994-02-08 1995-08-29 Novartis Ag Treatment of normotensive glaucoma with angiotensin ii antagonists
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
ES2552639T3 (es) 1998-07-10 2015-12-01 Novartis Pharma Ag Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos

Also Published As

Publication number Publication date
CY2007026I1 (el) 2009-11-04
SK312001A3 (en) 2001-06-11
KR20010079517A (ko) 2001-08-22
NZ527598A (en) 2005-04-29
NL300800I2 (xx) 2016-07-27
FR16C0008I1 (xx) 2016-04-15
ES2289814T3 (es) 2008-02-01
DE69936992T2 (de) 2008-03-06
SK285863B6 (sk) 2007-10-04
NZ509260A (en) 2003-09-26
JP2002520274A (ja) 2002-07-09
DE122007000055I1 (de) 2007-12-13
RU2450813C2 (ru) 2012-05-20
LU91358I2 (fr) 2007-11-06
NL300290I2 (nl) 2008-11-03
AU753486B2 (en) 2002-10-17
PT1096932E (pt) 2007-09-21
SI2322174T1 (sl) 2015-12-31
CA2678722C (en) 2013-08-27
AU5034999A (en) 2000-02-01
CA2336822C (en) 2009-11-17
CY2007026I2 (el) 2009-11-04
DK1096932T3 (da) 2007-10-15
EP2322174B1 (en) 2015-09-23
NO20010113D0 (no) 2001-01-08
RU2243768C2 (ru) 2005-01-10
KR100550167B1 (ko) 2006-02-08
EP1096932B1 (en) 2007-08-29
HU229383B1 (en) 2013-11-28
CY1107779T1 (el) 2010-07-28
CA2678722A1 (en) 2000-01-20
CN1234357C (zh) 2006-01-04
CY2016006I1 (el) 2016-10-05
IL140665A (en) 2012-12-31
TR200100062T2 (tr) 2001-06-21
CY2016006I2 (el) 2016-10-05
IL140665A0 (en) 2002-02-10
NL300290I1 (xx) 2007-11-01
DK2322174T3 (en) 2015-10-12
EP1870098A3 (en) 2010-07-07
CA2336822A1 (en) 2000-01-20
HK1036758A1 (en) 2002-01-18
HK1152897A1 (en) 2012-03-16
ATE371448T1 (de) 2007-09-15
PL194604B1 (pl) 2007-06-29
ES2552639T3 (es) 2015-12-01
EP2322174A3 (en) 2011-07-27
CN1312715A (zh) 2001-09-12
IL213926A0 (en) 2011-07-31
PT2322174E (pt) 2015-10-27
ZA200100232B (en) 2002-04-09
WO2000002543A3 (en) 2000-06-29
RU2012110522A (ru) 2013-09-27
CZ304359B6 (cs) 2014-03-26
NO2012013I1 (no) 2012-07-30
SG142116A1 (en) 2008-05-28
CN1733307A (zh) 2006-02-15
KR20040078140A (ko) 2004-09-08
EP1096932A2 (en) 2001-05-09
ID27664A (id) 2001-04-19
EP2322174A2 (en) 2011-05-18
FR16C0008I2 (fr) 2018-06-08
NO2012013I2 (no) 2014-10-27
DE69936992D1 (de) 2007-10-11
PL345897A1 (en) 2002-01-14
BR9912021A (pt) 2001-04-03
CZ299429B6 (cs) 2008-07-23
EP1870098A2 (en) 2007-12-26
NO331802B1 (no) 2012-04-10
NO20010113L (no) 2001-03-09
HUP0102828A2 (hu) 2002-04-29
CZ200187A3 (en) 2001-05-16
WO2000002543A2 (en) 2000-01-20
BE2016C011I2 (xx) 2018-12-04
SI1096932T1 (sl) 2008-04-30
HUP0102828A3 (en) 2002-11-28
CY1116770T1 (el) 2016-10-05

Similar Documents

Publication Publication Date Title
LU92992I2 (fr) Valsartan et amlodipine et leurs sels pharmaceutiquement acceptables
LU93074I2 (fr) Sacubitril/valsartan, y compris les sels pharmaceutiquement acceptables de celui-ci